We
are Kat and Kerry Logan, a sister-brother entrepreneurial team and the
co-founders of Advanced Vascular Therapies (AVT). We cared for our disabled
Mother (she suffered from multiple strokes (7+) and diabetes with very poor
circulation) for over 30 years. In her later years, our mother’s poor
circulation led to ‘non-healing wounds’ or ulcers on her legs/feet and
potential amputation. For our family, amputating our mother’s leg was not an
option. So, in that time we became skilled at wound care and prevention, and
from it, we developed innovative technology to aid in wound healing with the
larger goal to prevent amputation. We considered it a great privilege to have
our mother with us until she was 88 years old, and due to God’s grace, her
wonderful doctors, and our hard work and ingenuity she passed away with both
her legs and no ulcers (wounds) while she still lived in her own home, despite
her ailments.
We observed and met
our Mother’s needs in innovative ways that led us to create our company to help
others with similar needs.
Our
skillsets are complementary with backgrounds in Supervision (Kat) and
Electrical Engineering (Kerry) from Purdue University. We created AVT to help
people with poor circulation retain their independence and stay in their own
homes with non-invasive therapeutic options. AVT is a seed stage company and a
Purdue University Foundry client. AVT is currently in the prototyping stage of
a novel pneumatic compression device (PCD) that we designed to heal non-healing
ulcers. Our device took 5 months to completely heal a ‘non-healing
ulcer’ on our mother, much better than the standard of care device, which took
1.5 years on two separate occassions to heal her wounds. Further, our device,
used weekly, prevented further wound formation, despite her extremely poor
circulation.
AVT is proud to have Mr. Mike Hoffa lead our
product development. He has over 24 years experience in product development and
engineering support covering a broad range of medical devices and has a deep
working knowledge of the legal, regulatory, quality, and manufacturing
requirements. Mr. Hoffa worked at Hologic (VP Product
Development), Suros Surgical Systems (Director of
Engineering), and Cook Medical (Program Manager).
AVT
is also Blessed to work with GMI (a renowned Indiana
medical device manufacturer) and 316 Product Development (a prominent Indiana
full service product development firm).
Milestones:
AVT
developed a prototype of the novel PCD for non-healing ulcers that worked to
save their mother’s limb
AVT
received a patent for their novel PCD – April 2017 and has an additional
patents currently pending
AVT
won the local InnovateHER competition at the Purdue
Foundry in West Lafayette, IN – May 2017
AVT
received a USDA Phase I SBIR to fund development of the final prototype for
production – June 2017
AVT
received a USDA Phase II SBIR to fund further research and development of the
final prototype for production - ending August 2024
AVT
received a 2022 INTAP Grant from Indiana for further developing its software
and a 2024 INTAP Grant from Indiana to offset early manufacturing cost.
Going forward:
FDA approval expected
in 2025 with sales to follow and Multi-site NIH efficacy study pursued.